Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

依达拉奉 医学 改良兰金量表 随机化 麻醉 内科学 随机对照试验 临床试验 缺血性中风 缺血
作者
Jie Xu,Anxin Wang,Xia Meng,Gulbahram Yalkun,Chunxue Wang,Zhiqiang Gao,Dawei Chen,Yong Ji,Jun Xu,Deqin Geng,Runxiu Zhu,Bo Liu,Aiqin Dong,Hua Mu,Zhihong Lu,Shuya Li,Huaguang Zheng,Xia Chen,Yilong Wang,Xingquan Zhao
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:52 (3): 772-780 被引量:153
标识
DOI:10.1161/strokeaha.120.031197
摘要

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
叶十七完成签到,获得积分10
1秒前
52hezi完成签到,获得积分10
1秒前
不二酱的科研完成签到,获得积分10
2秒前
扬嘉諵发布了新的文献求助10
5秒前
精明的沅应助jiabaoyu采纳,获得10
5秒前
路路发布了新的文献求助10
5秒前
Jasper应助勤恳凡双采纳,获得10
7秒前
研友_VZG7GZ应助影子采纳,获得10
7秒前
8秒前
8秒前
梓歆发布了新的文献求助10
9秒前
科研小白完成签到,获得积分10
12秒前
李胜驳回了Ava应助
12秒前
WD发布了新的文献求助10
13秒前
量子星尘发布了新的文献求助10
13秒前
14秒前
拾寒完成签到,获得积分10
14秒前
虚幻初之发布了新的文献求助10
16秒前
小二郎应助小麻花采纳,获得10
19秒前
脑洞疼应助端庄涟妖采纳,获得10
19秒前
乖猫要努力应助sxy采纳,获得10
19秒前
99发布了新的文献求助10
20秒前
20秒前
21秒前
十一完成签到,获得积分10
21秒前
小米完成签到,获得积分20
23秒前
24秒前
24秒前
24秒前
25秒前
FashionBoy应助Sjingjia采纳,获得10
25秒前
25秒前
世界第一大庸医完成签到,获得积分10
26秒前
蓝心语发布了新的文献求助10
26秒前
27秒前
闪电侠发布了新的文献求助10
27秒前
田様应助oscarkwan采纳,获得10
27秒前
ding应助小麻花采纳,获得10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320